{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T05:28:23Z","timestamp":1736832503615,"version":"3.33.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,13]]},"DOI":"10.7759\/cureus.77387","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T01:10:14Z","timestamp":1736817014000},"source":"Crossref","is-referenced-by-count":0,"title":["Refractory Dysmenorrhea Managed With a Glucagon-Like Peptide-1 Agonist: A Case Report"],"prefix":"10.7759","author":[{"given":"Mary","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Swartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine D","family":"Elis\u00e8e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.08.108","article-title":"Nonsteroidal antiinflammatory drug resistance in\u00a0dysmenorrhea: epidemiology, causes, and\u00a0treatment","volume":"218","author":"Oladosu FA","year":"2018","unstructured":"Oladosu FA, Tu FF, Hellman KM. Nonsteroidal antiinflammatory drug resistance in\u00a0dysmenorrhea: epidemiology, causes, and\u00a0treatment. Am J Obstet Gynecol. 2018, 218:390-400. 10.1016\/j.ajog.2017.08.108","journal-title":"Am J Obstet Gynecol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17041191","article-title":"Inflammatory markers in dysmenorrhea and therapeutic options","volume":"17","author":"Barcikowska Z","year":"2020","unstructured":"Barcikowska Z, Rajkowska-Labon E, Grzybowska ME, Hansdorfer-Korzon R, Zorena K. Inflammatory markers in dysmenorrhea and therapeutic options. Int J Environ Res Public Health. 2020, 17:1191. 10.3390\/ijerph17041191","journal-title":"Int J Environ Res Public Health"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134187","article-title":"A U-shaped relationship between body mass index and dysmenorrhea: a longitudinal study","volume":"10","author":"Ju H","year":"2015","unstructured":"Ju H, Jones M, Mishra GD. A U-shaped relationship between body mass index and dysmenorrhea: a longitudinal study. PLoS One. 2015, 10:e0134187. 10.1371\/journal.pone.0134187","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004096","article-title":"Primary dysmenorrhea: diagnosis and therapy","volume":"136","author":"Ferries-Rowe E","year":"2020","unstructured":"Ferries-Rowe E, Corey E, Archer JS. Primary dysmenorrhea: diagnosis and therapy. Obstet Gynecol. 2020, 136:1047-58. 10.1097\/AOG.0000000000004096","journal-title":"Obstet Gynecol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001751.pub3","article-title":"Nonsteroidal anti-inflammatory drugs for dysmenorrhoea","volume":"2015","author":"Marjoribanks J","year":"2015","unstructured":"Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015, 2015:CD001751. 10.1002\/14651858.CD001751.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010067","article-title":"Non-hormonal treatment options for regulation of menstrual cycle in adolescents with PCOS","volume":"12","author":"Reiser E","year":"2022","unstructured":"Reiser E, Lanbach J, B\u00f6ttcher B, Toth B. Non-hormonal treatment options for regulation of menstrual cycle in adolescents with PCOS. J Clin Med. 2022, 12:67. 10.3390\/jcm12010067","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081989","article-title":"Therapeutic potential of glucagon-like peptide-1 agonists in polycystic ovary syndrome: from current clinical evidence to future perspectives","volume":"10","author":"Jensterle M","year":"2022","unstructured":"Jensterle M, Herman R, Jane\u017e A. Therapeutic potential of glucagon-like peptide-1 agonists in polycystic ovary syndrome: from current clinical evidence to future perspectives. Biomedicines. 2022, 10:1989. 10.3390\/biomedicines10081989","journal-title":"Biomedicines"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2174\/1871530315666150316124019","article-title":"Metformin and inflammation: its potential beyond glucose-lowering effect","volume":"15","author":"Saisho Y","year":"2015","unstructured":"Saisho Y. Metformin and inflammation: its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets. 2015, 15:196-205. 10.2174\/1871530315666150316124019","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.462","article-title":"Glucagon-like peptide agonists: a prospective review","volume":"7","author":"Mariam Z","year":"2024","unstructured":"Mariam Z, Niazi SK. Glucagon-like peptide agonists: a prospective review. Endocrinol Diabetes Metab. 2024, 7:e462. 10.1002\/edm2.462","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5152\/jtgga.2015.15232","article-title":"Impact of obesity on infertility in women","volume":"16","author":"Da\u011f Z\u00d6","year":"2015","unstructured":"Da\u011f Z\u00d6, Dilbaz B. Impact of obesity on infertility in women. J Turk Ger Gynecol Assoc. 2015, 16:111-7. 10.5152\/jtgga.2015.15232","journal-title":"J Turk Ger Gynecol Assoc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi SH","year":"2024","unstructured":"Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024, 15:20420188231222367. 10.1177\/20420188231222367","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2014.6.5.449","article-title":"Prostaglandin E2 induces IL-6 and IL-8 production by the EP receptors\/Akt\/NF-\u03baB pathways in nasal polyp-derived fibroblasts","volume":"6","author":"Cho JS","year":"2014","unstructured":"Cho JS, Han IH, Lee HR, Lee HM. Prostaglandin E2 induces IL-6 and IL-8 production by the EP receptors\/Akt\/NF-\u03baB pathways in nasal polyp-derived fibroblasts. Allergy Asthma Immunol Res. 2014, 6:449-57. 10.4168\/aair.2014.6.5.449","journal-title":"Allergy Asthma Immunol Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding JP","year":"2022","unstructured":"Wilding JP, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022, 24:1553-64. 10.1111\/dom.14725","journal-title":"Diabetes Obes Metab"},{"key":"ref17","article-title":"Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs)","author":"Latif W","year":"2025","unstructured":"Latif W, Lambrinos KJ, Patel P, Rodriguez R. Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs). StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52564","article-title":"Tendency of semaglutide to induce gastroparesis: a case report","volume":"16","author":"Chaudhry A","year":"2024","unstructured":"Chaudhry A, Gabriel B, Noor J, Jawad S, Challa SR. Tendency of semaglutide to induce gastroparesis: a case report. Cureus. 2024, 16:e52564. 10.7759\/cureus.52564","journal-title":"Cureus"},{"key":"ref19","article-title":"Recognizing the risks of chronic nonsteroidal anti-inflammatory drug use in older adults","volume":"18","author":"Marcum ZA","year":"2010","unstructured":"Marcum ZA, Hanlon JT. Recognizing the risks of chronic nonsteroidal anti-inflammatory drug use in older adults. Ann Longterm Care. 2010, 18:24-7.","journal-title":"Ann Longterm Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.08.001","article-title":"Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention","volume":"39","author":"Vonkeman HE","year":"2010","unstructured":"Vonkeman HE, van de Laar MA. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum. 2010, 39:294-312. 10.1016\/j.semarthrit.2008.08.001","journal-title":"Semin Arthritis Rheum"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/323277-refractory-dysmenorrhea-managed-with-a-glucagon-like-peptide-1-agonist-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T01:10:16Z","timestamp":1736817016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/323277-refractory-dysmenorrhea-managed-with-a-glucagon-like-peptide-1-agonist-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.77387","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,13]]}}}